Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

201812 citationsJournal Articlegold Open Access

Authors

William F. Regine · University of Maryland, Baltimore

Kathryn Winter · NRG Oncology

Ross A. Abrams · Rush University Medical Center

Howard Safran · Rhode Island Hospital

Ivan L. Kessel · The University of Texas Medical Branch at Galveston

Yuhchyau Chen · University of Rochester Medical Center

James A. Fugazzi

Abstract

In this prospective evaluation, postresection CA19-9 was a significant predictor of both LRR and DF, whereas SMS was not. These findings support consideration of adjuvant radiation therapy dose intensification in patients with elevated postresection CA19-9.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Gastrointestinal Tumor Research and Treatment Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Advances in Radiation Oncology

Volume 3, Issue 2, pp. 154-162

DOI: 10.1016/j.adro.2018.01.003

Field-Weighted Citation Impact: 0.47